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What you need to know
• Discuss treatment with people with stage 1 hypertension and a 10 year
risk for cardiovascular disease ≥10%
• Choice of antihypertensive drug treatment should take into account
patient preferences; a new decision aid has been produced to support
this
• Consistently maintain blood pressure below target, rather than aim for
a target
• Existing blood pressure targets have not been lowered; the benefits
and harms of lowering them could not be fully determined from current
evidence
• Asymptomatic, severe hypertension (≥180/120 mmHg) does not require
same day specialist review, but investigations for target organ damage
should be carried out as soon as possible
• The guideline now makes recommendations for people with type 2
diabetes
Hypertension is a leading global cause of morbidity and
mortality. More than 25% of the adult UK population has
hypertension, and in about 30% blood pressure remains
uncontrolled.1 In August, the National Institute for Health and
Care Excellence (NICE) published its updated guideline on the
diagnosis and management of hypertension. The guideline
reviews further evidence that has emerged since it was last
updated in 2011 from randomised trials investigating the
initiation, monitoring, and choice of antihypertensive treatment.
The scope of the updated guideline has increased to also include
people with type 2 diabetes, but does not make recommendations
for people with chronic kidney disease, established
cardiovascular disease, or hypertension in pregnancy.
This article summarises the most recent recommendations from
NICE and includes information considered to be most relevant
to primary care clinicians. Key changes to current practice
include offering drug treatment to people at a lower threshold
for 10 year risk of cardiovascular disease, emphasis on
maintaining blood pressure below target, and clarifying criteria
for same day specialist review in people with accelerated
hypertension.
Recommendations
NICE recommendations are based on systematic reviews of best
available evidence and explicit consideration of cost
effectiveness. When minimal evidence is available,
recommendations are based on the guideline committee (GC)’s
experience and opinion of what constitutes good practice.
Evidence levels for the recommendations are given in italics in
square brackets.
Diagnosing hypertension
Diagnosis of hypertension involves initial clinic blood pressure
measurements followed by measurements at home to confirm
the diagnosis (infographic, fig 1).
The previous guideline recommended measuring blood pressure
in both arms, and repeating initial clinic blood pressure
measurements if there is a difference of 20 mmHg between
arms. This update has reduced this cut off to 15 mmHg, in line
with evidence to suggest that even a small difference between
arms could be associated with an increased risk of cardiovascular
disease or vascular damage.
Treating hypertension
Lifestyle interventions
Lifestyle interventions are recommended for people with
hypertension (box 1). If blood pressure is not reduced
sufficiently with lifestyle interventions alone, start medication
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in combination with lifestyle interventions, taking into account
the patient’s individual needs.
Box 1: Lifestyle interventions (not updated)
• Offer lifestyle advice to people with suspected or diagnosed
hypertension, and continue to offer it periodically
• Ask about diet and exercise patterns, because a healthy diet and regular
exercise can reduce blood pressure. Offer appropriate guidance and
written or audiovisual materials to promote lifestyle changes
• Ask about alcohol consumption and encourage a reduced intake if the
person drinks excessively, because this can reduce blood pressure and
has broader health benefits. See the recommendations for practice in
the NICE guideline on alcohol use disorders: prevention
• Discourage excessive consumption of coffee and other caffeine rich
products
• Encourage people to keep their dietary sodium intake low, either by
reducing or substituting sodium salt, as this can reduce blood pressure
• Do not offer calcium, magnesium, or potassium supplements as a
method for reducing blood pressure
• Offer advice and help to smokers to stop smoking. See the NICE
guideline on stop smoking interventions and services
• Inform people about local initiatives by, for example, healthcare teams
or patient organisations that provide support and promote healthy
lifestyle change, especially those that include group work for motivating
lifestyle change
• Recommendations were not updated other than a review of the evidence
for relaxation therapies. The available randomised trial data were not
sufficient to determine the benefit or harms of these interventions, and
recommendations for relaxation therapies were removed from the
guideline. Evidence from the previous guideline was based on short
term blood pressure changes, and there was no evidence of a direct
benefit to people with hypertension, such as improving quality of life or
reducing cardiovascular events.
Starting antihypertensive drug treatment
Discuss people’s preferences for treatment or no treatment, and
use clinical judgment when considering treatment for people
with frailty or multimorbidity. Offer treatment to all people with
stage 2 hypertension (160/100-179/119 mmHg). For those with
stage 1 hypertension (140/90-159/99 mmHg), evidence from
randomised trials showed a benefit of treatment,2 3 and health
economic modelling found that treating people with stage 1
hypertension with a 10% cardiovascular disease risk was cost
effective because of reductions in cardiovascular events,
therefore:
•Discuss starting antihypertensive drug treatment, in addition
to lifestyle advice, with adults under 80 with persistent
stage 1 hypertension who have one or more of the
following:
o target organ damage (box 4)
o established cardiovascular disease (box 4)
o renal disease
o diabetes
o an estimated 10 year risk of cardiovascular disease of
10% or more.
(Updated recommendation) [Based on moderate to very
low quality randomised trial data and original economic
modelling]
•Consider antihypertensive drug treatment in addition to
lifestyle advice for adults under 60 with stage 1
hypertension and an estimated 10 year risk below 10%.
Bear in mind that 10 year cardiovascular risk may
underestimate the lifetime probability of developing
cardiovascular disease. [Based on very low quality
non-randomised data, the experience and opinion of the
GC, and on original economic modelling]
•Consider antihypertensive drug treatment in addition to
lifestyle advice for people over 80 with stage 1
hypertension if their clinic blood pressure is over 150/90
mmHg. Use clinical judgement for people with frailty or
multimorbidity. [Based on the experience and opinion of
the GC]
•For adults under 40 with hypertension, consider seeking
specialist evaluation of secondary causes of hypertension
and a more detailed assessment of the long term balance
of treatment benefit and risks. [Based on the experience
and opinion of the GC]
Box 4: Definitions
Established cardiovascular disease
Medical history of stroke or transient ischaemic attack, heart attack, angina,
narrowed peripheral arteries, or an interventional procedure. Cardiovascular
disease is a general term for conditions affecting the heart or blood vessels.
It is usually associated with a build up of fatty deposits inside the arteries
(atherosclerosis) and an increased risk of blood clots. It can also be associated
with damage to arteries in organs such as the brain, heart, kidneys, and eyes
through deposition of glassy material within the artery walls (arteriosclerosis).
Cardiovascular disease is one of the main causes of death and disability in
the UK, but it can often be prevented by leading a healthy lifestyle.
Stage 1 hypertension
Clinic blood pressure ranging from 140/90 mmHg to 159/99 mmHg and
subsequent ambulatory blood pressure daytime average or home blood
pressure monitoring average blood pressure ranging from 135/85 mmHg to
149/94 mmHg.
Stage 2 hypertension
Clinic blood pressure of 160/100 mmHg or higher but less than 180/120 mmHg
and subsequent ambulatory blood pressure daytime average or home blood
pressure average of 150/95 mmHg or higher.
Stage 3 or severe hypertension
Clinic systolic blood pressure of 180 mmHg or higher or clinic diastolic
blood pressure of 120 mmHg or higher.
Target organ damage
Damage to organs such as the heart, brain, kidneys, and eyes. Examples
are left ventricular hypertrophy, chronic kidney disease, hypertensive
retinopathy, or increased urine albumin: creatinine ratio
Accelerated hypertension
A severe increase in blood pressure to 180/120 mmHg or higher (and
often over 220/120 mmHg) with signs of retinal haemorrhage and/or
papilloedema (swelling of the optic nerve). It is usually associated with
new or progressive target organ damage and is also known as malignant
hypertension
Choosing antihypertensive drug treatment
A new patient decision aid has been developed by NICE to
facilitate discussions with patients about different types of
treatment, taking into account factors such as side effects,
contraindications, and the number of tablets taken per day.4 The
recommended sequence for medication titration is summarised
in the infographic. Insufficient evidence was identified to
recommend dual antihypertensive therapy when starting
treatment.
Blood pressure targets
Some international guidelines have reduced their blood pressure
targets on the basis of recent randomised trials including the
large multicentre US based SPRINT and ACCORD trials.5 6
Both trials compared systolic blood pressure treatment targets
of 140 mmHg with more intensive targets of 120 mmHg. Both
trials included people with established cardiovascular disease
and chronic kidney disease, therefore were not fully applicable
to this guideline. A subgroup analysis of SPRINT that excluded
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people with chronic kidney disease found a benefit of the lower
blood pressure targets for people without type 2 diabetes, in
terms of reducing mortality and cardiovascular events. However,
the lower blood pressure target was also associated with a greater
risk of harms such as acute kidney injury and hypotension. As
the trial was stopped early, the long term implications of these
harms were unclear. In addition, the evidence was not fully
applicable to UK clinical practice because of differences in the
methods for measuring blood pressure: the trial used automated
measurement set on a time delay and an isolated rest period,
which results in lower blood pressure readings than in routine
UK clinical practice.7 A lower systolic blood pressure target of
120 mmHg in the trial would not equate to the same blood
pressure target in UK practice. The evidence therefore was
unclear and insufficient to determine the benefits and harms of
lowering existing blood pressure targets. A subgroup analysis
of ACCORD that excluded people with established
cardiovascular disease also found no benefit of a lower blood
pressure target for people with type 2 diabetes.
Recommendations therefore reflect this, and focus on reducing
and maintaining blood pressure below the existing target of 140
mmHg when the person is subsequently monitored, as this is
not achieved in approximately 35% of people.1
•Reduce clinic blood pressure to below 140/90 mmHg and
maintain that level in adults under 80 with hypertension
•Reduce clinic blood pressure to below 150/90 mmHg and
maintain that level in adults over 80 with hypertension.
(Updated recommendation) [Based on moderate to very
low quality randomised data and based on the experience
and opinion of the GC]
Monitoring blood pressure
People with hypertension need review and monitoring to assess
their response to treatment, and to ensure that their blood
pressure remains below target. As discussed above, the update
recommends to “reduce clinic blood pressure to below” target,
rather than “aim for a target” as per the 2011 guideline. Evidence
was insufficient to strongly recommend blood pressure
monitoring at home, so instead recommendations advise the use
of home monitoring in people who choose to self-monitor their
blood pressure. Evidence on telemonitoring was limited, and
did not determine any additional benefits for patient outcomes.
As a result, this was not recommended.
•Use clinic blood pressure measurements to monitor the
response to lifestyle changes or drug treatment
•Advise people who choose to self-monitor their blood
pressure to use home blood pressure monitoring (box 2)
•Consider ambulatory or home blood pressure monitoring,
in addition to clinic blood pressure measurements, for
people with hypertension identified as having a white coat
effect or masked hypertension.
[Based on low to very low quality evidence and based on
the experience and opinion of the GC]
Box 2: Monitoring blood pressure
• When using ambulatory or home blood pressure monitoring to examine
the response to treatment in adults with hypertension, use the average
blood pressure level taken during the person’s usual waking hours.
Reduce and maintain blood pressure at the following levels:
– below 135/85 mmHg for adults under 80
– below 145/85 mmHg for adults over 80
– Measure standing and seated blood pressure in people with
hypertension and
♦ with type 2 diabetes or
♦ with symptoms of postural hypotension or
♦ aged 80 and over
• In people with a notable postural drop (more than 20 mmHg in systolic
blood pressure) or symptoms of postural hypotension, treat to a blood
pressure target based on standing blood pressure
• For people who choose to use home blood pressure monitoring, provide
– training and advice on using home blood pressure monitors
– information about what to do if they are not achieving their target
blood pressure
Be aware that the corresponding measurements for home blood pressure
monitoring are 5 mmHg lower than for clinic measurements.
• Provide an annual review of care for adults with hypertension to monitor
blood pressure, provide support, and discuss lifestyle, symptoms, and
medication [Not updated]
• For adults with type 2 diabetes on antihypertensive drug treatment when
diabetes is diagnosed, review blood pressure control and medications
used. Make changes only if there is poor control of blood pressure or
if current drug treatment is not appropriate because of microvascular
complications or metabolic problems [From the previous guideline on
type 2 diabetes in adults guideline (NICE guideline NG28)]
See box 2 for further details on how to monitor blood pressure.
Identifying who to refer for same day
specialist review
Asymptomatic, severe hypertension (≥180/120 mmHg) does
not require same day specialist review. The previous guideline
recommended immediate treatment for people with severe
hypertension regardless of other signs and symptoms. However,
referring everyone based on blood pressure alone may result in
a large volume of accident and emergency referrals when only
a small proportion have life threatening cases of accelerated
hypertension. It is not clear to many clinicians which patients
with extreme blood pressures need to be seen in secondary care
urgently. This guideline has therefore clarified the criteria for
those who do require treatment to be started immediately in the
community versus those who require same day specialist review
(including those with accelerated hypertension, suspected
pheochromocytoma, or life threatening symptoms) (box 3).
These updated recommendations reflect that target organ damage
investigations can be carried out quickly by non-specialists to
aid decision making and determine who may need urgent referral
or treatment. Evidence in this area was lacking, therefore these
recommendations were based on consensus. The committee
took into account the advantages and disadvantages of same
day referral and the balance between identifying people who
need urgent treatment against unnecessary use of resources.
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Box 3: Identifying accelerated hypertension: assessing for same
day review
• Refer people for specialist assessment, carried out on the same day,
if they have a clinic blood pressure of 180/120 mmHg and higher with
o signs of retinal haemorrhage or papilloedema (accelerated
hypertension) or
o life threatening symptoms such as new onset confusion, chest pain,
signs of heart failure, or acute kidney injury
• If a person has severe hypertension (clinic blood pressure of 180/120
mmHg or higher) but no symptoms or signs indicating same day referral,
carry out investigations for target organ damage as soon as possible:
o If target organ damage is identified, consider starting antihypertensive
drug treatment immediately, without waiting for the results of ambulatory
or home blood pressure monitoring
o If no target organ damage is identified, repeat clinic blood pressure
measurement within seven days
• Refer people for specialist assessment carried out on the same day if
they have suspected pheochromocytoma (for example, labile or postural
hypotension, headache, palpitations, pallor, abdominal pain, or
diaphoresis)
Implementation
Lowering the cardiovascular risk based threshold for starting
treatment in those with stage 1 hypertension will mean additional
people require treatment and monitoring, although data suggest
that approximately half of those who are newly recommended
treatment are already receiving it in primary care.8 Treating the
additional patients will require additional primary care
consultations but will lead to reduced numbers of cardiovascular
events. Investment will be needed to implement ambulatory
blood pressure monitoring in primary care settings that do not
currently offer it (despite being a recommendation of the 2011
guideline). Clinical and economic evidence shows ambulatory
blood pressure monitoring to be cost saving in the longer term
through improved accuracy of diagnosis, thus avoiding
unnecessary medication for those wrongly diagnosed as
hypertensive and avoiding cardiovascular events in those
wrongly diagnosed as normotensive. The guideline committee
acknowledges that costs and savings may not always fall on the
same setting (primary versus secondary care).
Further information on the guidance
Methods
• This guidance was developed by the National Guideline Centre in
accordance with NICE guideline development methods
(https://www.nice.org.uk/media/default/about/what-we-do/our-
programmes/developing-nice-guidelines-the-manual.pdf)
• A Guideline Committee was established by the National Guideline
Centre, which incorporated healthcare and allied healthcare
professionals (one hypertension specialist nurse, two physicians with
an interest in hypertension, one primary care nurse, two general
practitioners, one elderly care physician, one commissioner, one senior
pharmacist) and two lay members. In addition, the committee had one
co-opted member (one diabetologist)
• Review questions were developed based on key clinical areas of the
scope. Systematic literature searches, critical appraisals, evidence
reviews, and evaluations of cost effectiveness, where appropriate, were
completed for all review questions included within the update
• Quality ratings of the evidence were based on GRADE methodology
(www.gradeworkinggroup.org/). These relate to the quality of the
available evidence for assessed outcomes or themes rather than the
quality of the study
• The scope and draft of the guideline went through a rigorous reviewing
process, in which stakeholder organisations were invited to comment;
the committee took all comments into consideration when producing
the final version of the guideline
• A formal review of the need to update a guideline is usually undertaken
by NICE after its publication. NICE will conduct a review to determine
whether the evidence base has progressed substantially to alter the
guideline recommendations and warrants an update
• The guideline is available from the NICE website https://www.nice.org.
uk/guidance/ng136
Future research
The following areas were identified where more evidence was required. Further
evidence could help to inform future recommendations and ensure people are
receiving the best possible treatment
• Which automated blood pressure monitors are suitable for people with
hypertension and atrial fibrillation?
• In adults under 40 with hypertension (with or without type 2 diabetes),
what are the appropriate risk and blood pressure thresholds for starting
treatment?
• What is the optimum blood pressure target for people over 80 with
treated primary hypertension?
• Are there subgroups of people with hypertension who should start on
dual therapy?
• What is the clinical and cost effectiveness of relaxation therapies for
managing primary hypertension in adults in terms of reducing
cardiovascular events and improving quality of life?
• Which people with extreme hypertension (220/120 mmHg or higher) or
emergency symptoms should be referred for same day hospital specialist
assessment?
How patients were involved in the creation of this article
Committee members involved in this guideline update included lay members
who contributed to the formulation of the recommendations summarised here.
Guidelines into practice
Do you use ambulatory blood pressure monitoring (or home monitoring
if ambulatory monitoring isn’t suitable or tolerated) to diagnose
hypertension?
Do you offer drug treatment to people with stage 1 hypertension (who
have no other risk factors) if they have a 10 year cardiovascular disease
risk below 20%?
Do you check that people with hypertension maintain a blood pressure
that is below their target?
Guideline Committee members Elizabeth Clark, Elizabeth Denver, Mark Glover,
Judith Magowan, Terry McCormack, Irene McGill, Richard McManus, Lucy Pollock,
Mark Shapley, Alison Warren and Bryan Williams (until 10/10/2018).
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Figure
Fig 1 Infographic: Hypertension in adults: diagnosis and management
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2019;367:l5310 doi: 10.1136/bmj.l5310 (Published 21 October 2019) Page 6 of 6
PRACTICE
 o
n
 9 Novem
ber 2019 at University of Nottingham
. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l5310 on 21 October 2019. Downloaded from 
